Malaria Transmission-Blocking Vaccine Raw Materials

Transmission-blocking vaccines (TBVs) interrupt the malaria parasite life cycle within the mosquito vector by targeting sexual-stage and mosquito-stage antigens, and they are an essential component of malaria elimination research. The leading TBV targets are the pre-fertilization antigens Pfs230 and Pfs48/45, expressed on the surface of gametocytes and gametes, and the post-fertilization antigen Pfs25, expressed on zygotes and ookinetes. Clinical-stage candidates such as Pfs230D1M-EPA/AS01 and Pfs25M-EPA/AS01 have established these antigens as the most advanced TBV targets in development.

This portfolio provides the raw materials required to build, characterize, and quality-control TBV and CSP-based vaccine research programs: recombinant P. falciparum Pfs230D1, Pfs48/45, and Pfs25 antigens; full-length, truncated, and mosaic circumsporozoite protein (CSP) constructs; and a matched antibody panel including human, mouse, and rabbit monoclonal antibodies against CSP (CIS43 variants), P. vivax CSP (clone 2F2 and C483V), and polyclonal antibodies against the NANP and NVDP repeat regions. Sourcing antigens and matched antibodies from a single supplier streamlines assay development, comparability studies, and technology transfer for vaccine research and process development teams.

Platform Features and Product Advantages

• Clinical-target relevance. Antigens correspond to the most advanced TBV targets in clinical development (Pfs230D1, Pfs48/45, Pfs25) and to the CSP antigen underlying licensed malaria vaccines.
• Matched antigen-antibody sets. Recombinant antigens paired with characterized monoclonal antibodies (human CIS43 variants, PvCSP clone 2F2) enable immediate development of binding, competition, and relative-activity assays without sourcing antibodies separately.
• Multiple host species and formats. Human, mouse, and rabbit versions of key clones (CIS43_Var10, CIS43_Var2, 2F2) support assay development across preclinical species and enable species-appropriate detection reagents.
• Repeat-region resolution. Polyclonal antibodies against CSP (NANP)5, (NVDP)4, and the C-terminal region (a.a. 207-397) allow domain-resolved antigenicity assessment of CSP constructs.
• Program-ready documentation. Batch documentation and certificates of analysis support process development and technology transfer workflows.
• Bulk and custom supply. Research-scale through bulk quantities, custom tags, conjugation-ready formats, and program-specific specifications available on request.

References

1. Duffy, P. E., & Patrick Gorres, J. (2020). Malaria vaccines since 2000: progress, priorities, products. npj Vaccines, 5(1), 48.
2. Laurens, M. B. (2020). RTS,S/AS01 vaccine (Mosquirix): an overview. Human Vaccines & Immunotherapeutics, 16(3), 480-489.
3. El-Moamly, A. A., & El-Sweify, M. A. (2023). Malaria vaccines: the 60-year journey of hope and final success - lessons learned and future prospects. Tropical Medicine and Health, 51(1), 29.
4. Kisalu, N. K., et al. (2018). A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite. Nature Medicine, 24(4), 408-416.
5. Tripathi, H., Bhalerao, P., et al. (2023). Malaria therapeutics: are we close enough? Parasites & Vectors, 16(1), 130.